FDA delays tofacitinib decision

FDA extended the PDUFA date by three months for an NDA from Pfizer Inc. (NYSE:PFE) for tofacitinib to treat rheumatoid arthritis (RA). The new date is Nov. 21; it was Aug. 21. According to Pfizer, FDA...